Posted On: 09/13/2016 12:25:49 PM
Post# of 72447
Re: Loose Lips #27337
Thanks. I view it more specifically or rather more likely to be in the form of grants or other incentives.
Take a look at the second paragraph below:
Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
BEVERLY, MA–(Marketwired – July 15, 2015) – Cellceutix Corporation (CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of ovarian cancer.
The FDA’s Orphan Drug Designation program allows special incentives for sponsors planning to test a product for use in a rare disease or condition, defined as affecting fewer than 200,000 people in the United States. These incentives include federal grants, tax credits, and reduced filing fees during development or at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity in the United States.
- See more at: http://cellceutix.com/kevetrin/#sthash.acPjzaJF.dpuf
Take a look at the second paragraph below:
Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
BEVERLY, MA–(Marketwired – July 15, 2015) – Cellceutix Corporation (CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of ovarian cancer.
The FDA’s Orphan Drug Designation program allows special incentives for sponsors planning to test a product for use in a rare disease or condition, defined as affecting fewer than 200,000 people in the United States. These incentives include federal grants, tax credits, and reduced filing fees during development or at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity in the United States.
- See more at: http://cellceutix.com/kevetrin/#sthash.acPjzaJF.dpuf
(0)
(0)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
